KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Sarepta Therapeutics (SRPT) over the last 15 years, with Q3 2025 value amounting to $295.8 million.

  • Sarepta Therapeutics' Accumulated Expenses fell 1422.06% to $295.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $295.8 million, marking a year-over-year decrease of 1422.06%. This contributed to the annual value of $373.5 million for FY2024, which is 1857.67% up from last year.
  • As of Q3 2025, Sarepta Therapeutics' Accumulated Expenses stood at $295.8 million, which was down 1422.06% from $377.4 million recorded in Q2 2025.
  • In the past 5 years, Sarepta Therapeutics' Accumulated Expenses ranged from a high of $419.0 million in Q4 2022 and a low of $180.6 million during Q1 2021
  • For the 5-year period, Sarepta Therapeutics' Accumulated Expenses averaged around $321.4 million, with its median value being $326.9 million (2023).
  • Per our database at Business Quant, Sarepta Therapeutics' Accumulated Expenses soared by 6696.06% in 2022 and then plummeted by 2482.1% in 2023.
  • Over the past 5 years, Sarepta Therapeutics' Accumulated Expenses (Quarter) stood at $271.7 million in 2021, then skyrocketed by 54.21% to $419.0 million in 2022, then decreased by 24.82% to $315.0 million in 2023, then grew by 18.58% to $373.5 million in 2024, then decreased by 20.81% to $295.8 million in 2025.
  • Its Accumulated Expenses stands at $295.8 million for Q3 2025, versus $377.4 million for Q2 2025 and $391.6 million for Q1 2025.